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3,30-Diindolylmethane (DIM), a major acid-condensation product or metabolite of indole-3-carbinol
which is found in cruciferous vegetables, has been shown to have anticancer, anti-inﬂammatory, and
multiple immune stimulating effects. However, its function in bone metabolism is poorly understood.
This study evaluated the effect of DIM on bone mass in mice under physiological and pathological
conditions. Eight-week-old female mice received injections of a vehicle or 0.1 mg/g of DIM, twice a week
for four weeks. We found that DIM treatment signiﬁcantly increased bone mass as assessed by dual-
energy X-ray absorptiometry (DEXA) and micro-computed tomography (mCT). Further, Bone histo-
morphometric analyses showed that this treatment signiﬁcantly reduced bone resorption parameters,
but did not increase bone formation parameters. Furthermore, we use ovariectomized (OVX)-induced
osteoporotic mouse model, and explore function of DIM in skeletal pathological processes. Bone
phenotype analyses revealed that the administration of DIM in this study effectively prevented OVX-
induced bone loss resulting from increased bone resorption. Our results demonstrated that DIM
increased bone mass by suppressing osteoclastic bone resorption in bone metabolism under both
physiological and pathological conditions. Accordingly, DIM may be of value in the treatment and the
possible prevention of bone diseases characterized by bone loss, such as postmenopausal osteoporosis.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
3,30-Diindolylmethane (DIM) is an acid-condensation product of
indole-3-carbinol. Indole-3-carbinol is an autolysis product of
glucosinolate that is present in vegetables belonging to the genus
Brassica in the mustard family, and includes food sources such as
turnips, kale, broccoli, cabbage, Brussels sprouts, and cauliﬂower
(1). DIM was readily detected in the liver and feces of rodents fed
indole-3-carbinol, whereas the original indole-3-carbinol was not
detected in these animals (2). Studies performed by Reed et al.
indicated that indole-3-carbinol was not detectable in the plasma
of women ingesting indole-3-carbinol, and DIM was the onlyhophysiology, Proteo-Science
ity, Shitsukawa, Toon, Ehime
960 5953.
acological Society.
. Production and hosting by Elseindole-3-carbinol-derived compound detected in plasma (3). These
results suggest that DIM, but not indole-3-carbinol is the pre-
dominant bioactive compound.
DIM is a natural antagonist of the aryl hydrocarbon receptor
(AhR), also known as the dioxin receptor. AhR is a ligand-activated
transcription factor that belongs to a transcription factor super-
family characterized by structural motifs of basic helix-loop-helix
(bHLH)/Per-AhR nuclear translocator (Arnt)-Sim (PAS) domains,
which also includes the hypoxia-inducible factor (HIFs) (4).
Recently, our laboratory and the studies of others have determined
there is increased bone mass with reduced bone resorption in AhR
knockout (AhR/) mice (5,6), suggesting that AhR plays a signiﬁ-
cant role in the maintenance of bone homeostasis, and selective
inhibition of AhR activity might be a new direction for molecular-
targeted prevention and treatment of bone diseases.
Emerging preclinical evidence shows that DIM possesses anti-
carcinogenic effects in experimental animals, induces apoptosis in
breast, ovarian, cervix, prostate, colon, and pancreatic cancer cellsvier B.V. This is an open access article under the CC BY-NC-ND license (http://
T.-y. Yu et al. / Journal of Pharmacological Sciences 127 (2015) 75e8276(7e18), the effects of which are mediated by alterations in multiple
signaling pathways (1,17,18). DIMmay have anti-inﬂammatory (19),
estrogen metabolism modulating (20), and immune stimulating
functions (10,21e23). In vitro evidence indicates that DIM was able
to inhibit the differentiation of osteoclasts via inhibition of RANKL-
mediated cell signal transduction (19,24). However, the effect of
DIM on bone metabolism in vivo is poorly understood.
In the present study, we assessed the bone phenotype of mice
treated with DIM under physiological and pathological conditions.
2. Materials and methods
2.1. Animals
Female C57/BL6 mice were purchased from CLEA Japan Inc. All
mice were housed in a speciﬁc-pathogen-free (SPF) facility under
climate-controlled conditions with a 12-h light/dark cycle andwere
provided with water and a standard diet (CE-2, CLEA, Japan) ad
libitum. All animals were maintained and examined according to
the protocol approved by the Animal Care and Use Committee of
the Ehime University.
2.2. DIM treatment
Female C57/BL6J mice were injected with the corn oil (Wako,
Japan) vehicle only or DIM (SigmaeAldrich Co, D9568-5G) starting
when they were eight weeks old. DIM was dissolved in corn oil and
intraperitoneal injected at 0.1 mg/g body weight, twice a week for
four weeks. Mice were analyzed at 12 weeks of age.
2.3. Ovariectomy-induced osteoporotic mouse model
Female C57/BL6J mice were bilaterally ovariectomized (OVX) or
sham-operated at 6 weeks of age. Two weeks after surgery, the 8-
week-old sham mice received intraperitoneal injections of the
corn oil (Wako, Japan) vehicle only, OVX mice received intraperi-
toneal injections of the corn oil vehicle only or DIM (SigmaeAldrich
Co, D9568-5G) delivered in the vehicle. Six weeks after surgery, the
12-week-old mice were euthanized and subjected to micro-
computed tomography (mCT) and bone histomorphometry.
2.4. Dual-energy X-ray absorptiometry (DEXA)
The bonemineral density (BMD) of whole femurs was measured
by DEXA using a bone mineral analyzer (DCS-600EX: ALOKA)
(25,26).
2.5. Micro-computed tomography (mCT) analysis
mCT analysis was performed as described using a mCT system
(mCT35, SCANCOMedical, Bruttisellen, Switzerland) (25,27). Brieﬂy,
466 slices were acquired, starting just beneath the end of the
growth plate, thus including both the primary and secondary
spongiosa. A region 1.8 mm in length at the distal metaphyseal
secondary spongiosa (300 slices) was also selected for analysis.
Three-dimensional reconstructions were generated and analyzed
according to the guideline (28).
2.6. Bone histomorphometric analyses
Bone histomorphometry was performed on the vertebrae as
previously described (26,27). Bone histomorphometric analyses
were performed using the OsteoMeasure analysis system (Osteo-
Metrics Inc., GA, USA) according to the American Society for Bone
and Mineral Research (ASBMR) guidelines (29).2.7. Statistical analysis
Data were analyzed using a two-tailed Student's t-test. For all
graphs, data are represented as mean± standard deviation (SD). A
p-value less than 0.05 was considered statistically signiﬁcant
(*p< 0.05; **p< 0.01; ***p< 0.001).
3. Results
3.1. DIM increases bone mass in mice under physiological
conditions
BMD DEXA measurements of the mice treated with or without
DIM, and showed the distal femoral BMD of mice treated with DIM
was signiﬁcantly higher compared with controls (Fig. 1A). To assess
changes in the three-dimensional trabecular architecture between
mice treated with DIM and their controls, mCT was performed.
Increased trabecular bone mass at the distal femur in mice treated
with DIM was observed via mCT analysis (Fig. 1B and C). The
trabecular bone of mice treated with DIM exhibited signiﬁcantly
higher measurements compared to those of their controls for the
following parameters: BV/TV, Tb.N, BMD, and Conn.D; whereas a
decrease versus controls was evident for Tb.Sp and SMI (Fig. 1D). To
further conﬁrm our results, we also performed mCT analysis in
tibiae. Compared with control mice, trabecular bone mass at the
proximal tibiae in mice treated with DIM was also substantially
greater (Fig. 1EeG). To examine mineralized bone volume in the
vertebral trabecular bone of mice treated with DIM, we performed
von Kossa/van Gieson staining. Consistent with the femur and
tibiae, histological analyses of the vertebrae also demonstrated that
mice treated with DIM displayed signiﬁcantly greater vertebral BV/
TV (Fig. 2A and B). Taken together, these results indicate that DIM
increased bone mass in bone homeostatic maintenance under
physiological conditions.
3.2. DIM suppresses bone resorption in mice under physiological
conditions
To deﬁne the cellular basis of the increased bone mass pheno-
type observed in mice treated with DIM, bone histomorphometry
was performed. The number and/or activity of osteoblasts/osteo-
clasts were examined in the lumbar vertebrae at L3 and L4 of mice
treated with DIM and their controls. Parameters related to osteo-
clastic bone resorption, such as N.Oc/B.Pm and Oc.S/BS, were
signiﬁcantly decreased in mice treated with DIM compared with
their controls (Fig. 2C and D). Our in vivo ﬁndings in relation to
osteoclasts support those in vitro ﬁndings previously reported by
another group (19,24). Although mice treated with DIM were
assessed as having fewer osteoblasts based on osteoblast number
and osteoblast surface, no signiﬁcant effect was observed (Fig. 1E
and F). In addition, MAR and BFR/BS also were not altered in mice
treated with DIM (Fig. 2G and H). Collectively, these results
demonstrate that the phenotypic increase in bone mass in mice
treated with DIM under physiological conditions, is a result of
reduced osteoclastic bone resorption, rather than increased oste-
oblastic bone formation.
3.3. DIM prevented bone loss induced by ovariectomy
The data that have been described up to this point for mice
conﬁrm the important role of DIM in bone homeostasis under
physiological conditions. To evaluate the therapeutic potential of
DIM, an estrogen-deﬁcient OVX mouse model was used. DIM was
administered twice a week for four weeks, starting 2 weeks after
OVX. mCT analysis revealed that OVX mice exhibited signiﬁcant
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Fig. 1. Increased bone mass in mice treated with 3,30-diindolylmethane (DIM). Dual-energy X-ray absorptiometry (DEXA) measurements of whole femurs frommice treated with or
without DIM. Bone mineral density (BMD) was assessed for 20 equal cross-sectional divisions of femurs (A). Micro-computed tomography (mCT) analyses of femurs and tibiae in
mice treated with or without DIM (BeG). Representative images of trabecular bone in the distal femur (B) and in axial sections of the distal metaphysis (C). mCT parameters of the
distal femurs are shown in (D). Representative images of trabecular bone in proximal tibiaes (E) and axial sections of the proximal metaphysis (F). mCT parameters of the proximal
tibiaes are shown in (G). Scale bars indicate 1.0 mm. Data are represented as mean± standard deviation (SD). A p-value less than 0.05 was considered statistically signiﬁcant
(*p < 0.05; **p < 0.01; ***p < 0.001).
T.-y. Yu et al. / Journal of Pharmacological Sciences 127 (2015) 75e82 77trabecular bone loss in the distal femur (Fig. 3A and B) and proximal
tibiae (Fig. 3C and D) when compared with shammice. Quantitative
measurements indicated a lower BV/TV, Tb.N, BMD, and Conn.D, as
well as greater Tb.Sp and SMI in OVX mice when compared with
sham mice (Fig. 3E and F). In addition, bone histomorphometric
analyses revealed trabecular bone loss in the vertebrae of OVXmice(Fig. 4A and D). However, DIM-treated OVX mice exhibited a
signiﬁcantly higher trabecular bone mass in the distal femur
(Fig. 3A and B), proximal tibiae (Fig. 3C and D), and vertebrae
(Fig. 4A and C) when compared with OVX vehicle-treated mice. It
was shown that BV/TV, Tb.N, BMD, and Conn.D were higher,
whereas Tb.Sp and SMI were lower in DIM-treated OVX mice when
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T.-y. Yu et al. / Journal of Pharmacological Sciences 127 (2015) 75e8278compared with vehicle-treated OVX mice (Fig. 3E and F). Taken
together, these results indicated that DIM treatment effectively
prevented OVX-induced changes in bone that could result in an
osteopenic condition.
3.4. DIM inhibited bone resorption in an OVX mouse model
To explore the cellular mechanism by which DIM prevented
bone loss in a mouse model of osteoporosis, we ﬁrst examined
whether changes occurred in osteoclastic bone resorption in DIM-
treated OVX mice using TRAP staining and histomorphometric
analyses. As shown in Fig. 4B and D, compared with sham mice,
OVX mice exhibited a signiﬁcant increase in osteoclastic bone
resorption parameters, such as N.Oc/B.Pm and Oc.S/BS. However,
DIM-treated OVX mice exhibited decreased osteoclastic bone
resorption when compared with vehicle-treated OVX mice. To
examine whether osteoblastic bone formation is abnormal in DIM-
treated OVX mice, we performed toluidine blue staining. No other
differences between the DIM-treated OVX mice and the vehicle-
treated OVX mice were observed in osteoblastic bone formation
parameters such as N.Ob/B.Pm and Ob.S/BS (Fig. 4E). These results
indicate that DIM treatment prevented ovariectomy-induced bone
loss by inhibiting bone resorption.
4. Discussion
Bone remodeling involves the removal of old or damaged bone
by osteoclasts (bone resorption) and the subsequent replacementof new bone formed by osteoblasts (bone formation). Normal bone
remodeling requires a tight coupling of bone resorption to bone
formation, so that there is no appreciable alteration in bonemass or
quality after each remodeling cycle (30,31). However, this impor-
tant physiological process can be perturbed by various endogenous
factors such as menopause-associated hormonal changes, second-
ary diseases, and exogenous factors such as drugs and pollutants.
Osteoclastic bone resorption may be substantially increased, and
bone mass can be subsequently decreased, as a result of various
pathologies such as osteoporosis, rheumatoid arthritis, and meta-
static bone disease (32e35). Therefore, suppressing osteoclastic
bone resorption can be prophylactic and/or an important thera-
peutic strategy for combating these types of bone diseases.
AhR plays a critical role in various pathological and physiological
processes. Our laboratory, and other groups that have more
recently evaluated systemic AhR KO mice, have found that bone
mass increased, and bone resorption (as assessed by N.Oc/B.Pm and
Oc.S/BS) decreased, as a result of the aryl hydrocarbon receptor-
deﬁciency in AhR KO mice (5,6). On the other hand, using trans-
genic mice expressing constitutively active AhR, Wejheden C et al.
found that bone mass decreased in conjunction with an increase in
bone resorption markers, which included protein levels of the
osteoclast collagenase cathepsin K and serum level of C-telopeptide
of type I collagen (CTX), in female transgenic mice (36). These data
showed that AhR decreased bone mass by increasing bone
resorption in vivo, and suggested that selective inhibition of the
AhR pathway may increase bone mass through suppression of
osteoclastic bone resorption.
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AhR antagonists (37e41). It was recently reported that these nat-
ural compounds increase bone mass (42e45). DIM treatment also
showed notable inhibitory effects on the activity of AhR (46,47).
Therefore, our hypothesis is that DIM may also inﬂuence bone
mass. To test this hypothesis, 8-week-old female mice received
injections of 0.1 mg/g of DIM, twice a week for four weeks. We
performed DEXA and mCT, and found that DIM treatment signiﬁ-
cantly increased BMD, BV/TV, Tb.N and Conn.D, and decreased
Tb.Sp and SMI in the distal femur and proximal tibiae of mice
(Fig. 1). In addition, DIM treatment also increased bone mass in
vertebral trabecular bone (Fig. 2A and B). In general, distal femur,
proximal tibia and L3, L4 lumbar vertebrae are active in bone
metabolism because of their higher contents of trabecular bone. If
bone mass or bone metabolism has any changes, the abnormality
would be preferentially presented in above region. Our data clearly
showed that DIM also enhanced bone mass under physiological
conditions.
Bone histomorphometric analyses demonstrated that DIM
treatment signiﬁcantly reduced the bone resorption parameters
N.Oc/B.Pm and Oc.S/BS (Fig. 2C and D), but did not inﬂuence the
bone formation parameters N.Ob/B.Pm, Ob.S/BS, MAR, BFR/BS
(Fig. 2EeH). Our in vivo ﬁndings in osteoclasts support thosein vitro results that were previously reported by another group
(19,24). Dong et al. determined that DIM might effectively inhibit
the expression of receptor activator of nuclear factor kappa-B
ligand (RANKL), leading to the suppression of osteoclastogenesis
(19). Li et al. found that DIM treatment was able to inhibit the
differentiation of osteoclasts through the inhibition of cell signal
transduction in RANKL (24). However, our in vivo ﬁndings in os-
teoblasts are inconsistent with in vitro results reported by Li et al
who determined that DIM could inhibit the differentiation of os-
teoblasts by inhibiting the expression of periostin, one of the
important genes for osteoblast differentiation (24). Collectively, our
results demonstrate that DIM increases bone mass by suppressing
osteoclastic bone resorption, but not by increasing osteoblastic
bone formation, under physiological conditions.
Osteoporosis is a common bone disease. Postmenopausal
women generally lose bone due to diminished ovarian estrogen and
a subsequent increase in bone resorption (32,48). Previous studies
have shown that inﬂammatory cytokines such as interleukin (IL)-1
and prostaglandin E2 (PGE2) may be involved in the mechanism of
bone loss attributable to estrogen insufﬁciency (49e51). PGE2 is
mainly produced by cyclooxygenase-2 (COX-2) in osteoblasts and
acts as a potent stimulator of bone resorption (52,53). IL-1 is known
to induce PGE2 production by osteoblasts and RANKL expression on
T.-y. Yu et al. / Journal of Pharmacological Sciences 127 (2015) 75e82 81their surface. Recently, several group studies revealed that DIM
reduces inﬂammation (19,54). Kim et al. investigated DIM inhibi-
tion of the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced
increases in the expression of COX-2, inducible nitric oxide syn-
thase, chemokine (C-X-C motif) ligand (CXCL) 5, and IL-6 in mouse
skin (54). DIM also inhibited NFkB DNA binding activity, the nuclear
translocation of p65, and the degradation of inhibitor of kBa in TPA-
stimulated mouse skin (54). Dong et al. found that DIM attenuates
experimental arthritis by reducing the expression of several in-
ﬂammatory cytokines including tumor necrosis factor-alpha (TNF-
a), IL-1 and nitric oxide (19). Moreover, Kim et al. showed that DIM
attenuates colonic inﬂammation and tumorigenesis with a signiﬁ-
cant reduction in colonic myeloperoxidase activity and production
of PGE2, nitric oxide, and pro-inﬂammatory cytokines (55). This
series of evidence enables us to begin to evaluate whether DIM
could potentially prevent bone loss in women with post-
menopausal osteoporosis. To enhance bone loss in themice, an OVX
model with diminished estrogen producing capacity was utilized.
This model has been widely used in research to approximate the
type of condition that can be an etiological factor in pathological
bone loss in postmenopausal women andwhich could possibly lead
to a condition of osteoporosis. Bone phenotypic analyses in this
mouse model showed that DIM treatment could effectively prevent
OVX-induced bone loss by suppressing osteoclastic bone resorption
(Figs. 3 and 4). Our results suggest that DIM may be of value in the
prevention and treatment of postmenopausal osteoporosis.
A limitation of this study is that the validation of function of DIM
in bone metabolism under pathological conditions was performed
using only an OVX mouse model. Future studies are required to
determine whether DIM would likewise protect against bone loss
in other mouse models with conditions such as lipopolysaccharide-
induced inﬂammatory bone loss. In addition, precise molecular
mechanisms still remain elusive, even though our study directly
elucidated that DIM plays a signiﬁcant role in the control of bone
mass under physiological and pathological conditions, as deter-
mined by the use of DEXA, mCT, and bone histomorphometric an-
alyses. Further studies are needed to more profoundly comprehend
the detailed molecular basis of the function of DIM in bone meta-
bolism, such as examining whether the function of DIM is related
with AhR in osteoclasts using osteoclast-speciﬁc AhR deletionmice.
In conclusion, by analyzing the bone phenotype in experimental
animal models, we found that DIM treatment signiﬁcantly
increased bone mass by suppressing osteoclastic bone resorption
under both physiological and pathological conditions. Therefore,
we believe that DIM may be a potential prophylactic and/or ther-
apeutic agent for bone diseases, such as postmenopausal
osteoporosis.
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